BLOCKADE OF ANGIOTENSIN II TYPE I RECEPTOR (AT1) AND CC CHEMOKINE RECEPTOR 2 (CCR2) HETEROMERS IN PROGRESSIVE CHRONIC KIDNEY DISEASE

被引：0
|
作者：
Zhang, Y. [1 ]
Kelly, R. [1 ]
Cox, A. [1 ]
Williams, J.
Mccall, L.
Pfleger, K. [2 ]
Kelly, D. [1 ]
机构：
[1] Univ Melbourne, Melbourne, Vic 3010, Australia
[2] Univ Western Australia, Nedlands, WA 6009, Australia
来源：
NEPHROLOGY | 2013年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
083
引用
收藏
页码：36 / 36
页数：1
相关论文
共 50 条
  • [31] Blockade of type 1 CC chemokine receptor (CCR1) with metRANTES in Experimental Autoimmune Encephalomyelitis (EAE)
    Matsui, M
    Weaver, J
    Proudfoot, AEI
    Rao, A
    Ransohoff, RM
    NEUROLOGY, 2001, 56 (08) : A467 - A467
  • [32] Angiotensin AT2 receptor contributes to cardiovascular remodeling of aged rats during chronic AT1 receptor blockade
    Jones, ES
    Black, MJ
    Widdop, RE
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (5-6) : A13 - A13
  • [33] Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged SHR during chronic AT1 receptor blockade
    Jones, ES
    Black, MJ
    Widdop, RE
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (01) : 252 - 252
  • [34] Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged rats during chronic AT1 receptor blockade
    Jones, ES
    Black, MJ
    Widdop, RE
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (05) : 1023 - 1030
  • [35] Angiotensin AT2 receptor contributes to cardiovascular remodelling of aged SHR during chronic AT1 receptor blockade
    Jones, ES
    Black, M
    Widdop, RE
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2005, 32 (07) : A14 - A14
  • [36] Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density
    Munzenmaier, DH
    Greene, AS
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (02): : H512 - H516
  • [37] Discovery of BMS-741672, a potent, selective, and orally bioavailable antagonist of CC Chemokine Receptor 2 (CCR2)
    Carter, Percy H.
    Yang, Michael G.
    Xiao, Zili
    Cherney, Robert J.
    Batt, Douglas G.
    Brown, Gregory D.
    Chen, Jing
    Cvijic, Mary Ellen
    De Lucca, George V.
    Duncia, John V.
    Ford, Gregory
    Gardner, Daniel S.
    Gillooly, Kathleen
    Ko, Soo S.
    Mandlekar, Sandhya
    Marathe, Punit
    McKinnon, Murray
    Mcintyre, Kim
    Murray, Judith
    Pang, Jian
    Reilly, Timothy P.
    Mo, Ruowei
    Rose, Anne
    Salter-Cid, Luisa
    Santella, Joseph B.
    Shen, Ding Ren
    Shi, Qing
    Srivastava, Anurag
    Tebben, Andrew J.
    Xie, Jenny
    Xu, Songmei
    Zhao, Qihong
    Barrish, Joel C.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [38] Design and synthesis of 3-alkylsulfonylmethyl cyclohexylaminobenzamide-derived inhibitors of CC chemokine receptor 2 (CCR2)
    Yang, Michael G.
    Batt, Douglas G.
    Cherney, Robert J.
    Mandlekar, Sandhya
    Cvijic, MaryEllen
    Zhao, Qihong
    Barrish, Joel C.
    Carter, Percy H.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [39] DISRUPTION OF THE CCR2 CHEMOKINE RECEPTOR PATHWAY OVERCOMES THERAPEUTIC RESISTANCE TO PD-1 BLOCKADE IN MALIGNANT GLIOMA
    Flores-Toro, Joseph
    Luo, Defang
    Campbell, James
    Charo, Israel
    Singh, Rajinder
    Schall, Thomas
    Datta, Meenal
    Jain, Rakesh
    Mitchell, Duane
    Harrison, Jeffrey
    NEURO-ONCOLOGY, 2019, 21 : 119 - 119
  • [40] Inhibition of MCP-1/CCR2 Signaling Pathway is Important for Reduction of Ischemic Brain Damage With AT1 Receptor Blockade
    Tsukuda, Kana
    Mogi, Masaki
    Iwanami, Jun
    Min, Li-Juan
    Jing, Fei
    Oshima, Kousei
    Horiuchi, Masatsugu
    HYPERTENSION, 2011, 58 (05) : E179 - E179
12345